SI
GYRE icon

Stephens Inc’s Gyre Therapeutics GYRE Stock Holding History

Stephens Inc’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,870
Closed -$11K – 1201
2022
Q3 		$11K Sell
2,870
-2,035
-41% -$25.8K ﹤0.01% 1194
2022
Q2 		$65K Sell
4,905
-56
-1% -$372 ﹤0.01% 1151
2022
Q1 		$25K Buy
4,961
+1,070
+27% +$5.3K ﹤0.01% 1297
2021
Q4 		$27K Buy
3,891
+1,646
+73% +$28.1K ﹤0.01% 1313
2021
Q3 		$69K Sell
2,245
-6
-0.3% -$197 ﹤0.01% 1284
2021
Q2 		$73K Buy
2,251
+883
+65% +$30.3K ﹤0.01% 1271
2021
Q1 		$52K Buy
+1,368
New +$62.5K ﹤0.01% 1244
2020
Q4 		– Sell
-1,653
Closed -$53K – 1238
2020
Q3 		$53K Buy
+1,653
New +$64.7K ﹤0.01% 1126

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Stephens Inc's GYRE Position: Q4 2022 in Review

Stephens Inc sold out of Gyre Therapeutics (GYRE) in Q4 2022, closing a stake of 2,870 shares — an estimated $11K sold.

Stephens Inc first reported a position in GYRE in Q3 2020 and held it in 8 quarters. The position peaked at $73K in Q2 2021. 34 funds tracked by Wall St. Rank hold GYRE as of Q4 2022.

  • Stephens Inc reported no remaining Gyre Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Stephens Inc sold 2,870 Gyre Therapeutics shares in Q4 2022, an estimated $11K.
  • Stephens Inc first reported a position in Gyre Therapeutics in Q3 2020 and held it in 8 quarters.
  • Stephens Inc's Gyre Therapeutics position peaked at $73K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2022.

Based on Stephens Inc's 13F filing for Q4 2022, filed 25 Jan 2023.